Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
Announcement on Reduction in Amounts of Stated Capital and Capital Reserves and Appropriation of Other Capital Surplus
Notice regarding partial amendment of the Articles of Incorporation
Notice regarding changes in certified public accountants
Notice Regarding the Variance between consolidated results and results of the previous year, non-consolidated results and results of the previous year
Notice Regarding the Recording of Non-Operating Income (Foreign Exchange Income)
2024 Fiscal Year End Business and Financial report
Consolidated Financial Results for the Fiscal Year Ended December 31, 2024 [Japanese GAAP]
LAMA2-CMD Patent Granted in Japan
JCR Pharmaceuticals and Modalis Therapeutics Announce Transition to the Next Phase of Joint Research Agreement for Development of Novel Gene Therapy
Notice Regarding the Occurrence of an Incident of Electronic Fraud at a Subsidiary and the Recording of an Extraordinary Loss
Notice Regarding the Recording of Non-Operating Income (Foreign Exchange Income)
Financial Results for the Nine Months Ended September 30, 2024
Consolidated Financial Results for the Nine Months Ended September 30, 2024 [Japanese GAAP]
MDL-101 for the Treatment of Congenital Muscular Dystrophy Type 1a has been granted Orphan Drug Designation in the US by FDA
FDA Grants Rare Pediatric Disease Designation to MDL-101 for the treatment of congenital muscular dystrophy type 1a (LAMA2-CMD)
Modalis Therapeutics to Present Epigenome Editing Technology (CRISPR-GNDM) and Data at the 5th Annual Genome Editing Therapeutics Summit
DMPK Patent Granted in Japan